Weight maintenance on cost-effective antiobesity medications after 1 year of GLP-1 receptor agonist therapy: a real-world study
Preparing the patient for what to expect fosters realistic expectations, builds trust, and encourages adherence to therapy
Dr Schmidt, a Research Manager at the AWRI, collaborated on the four-year project with the University of Adelaides Dr David Jeffery and Dr Gabriel Perrone from University of Western Sydney
While this effect typically diminishes as the body adjusts, it provides indirect evidence that the nitric oxide pathways are responding to the peptide
FDA legalisation permits compounded alternatives to be marketed when a drug is in shortage, as semalgutide was from 2022 through early 2025
When those are ignored, even the best protocol underperforms